Immunogenicity of anthracyclines: moving towards more personalized medicine

Trends in Molecular Medicine

Volumn 14, Issue 4, 2008, Pages 141-151

  Apetoh, Lionel ^a   Mignot, Grégoire ^a   Panaretakis, Theocharis ^a   Kroemer, Guido ^a   Zitvogel, Laurence ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMRUBICIN; ANTHRACYCLINE DERIVATIVE; ANTIBODY; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CALRETICULIN; CD4 ANTIBODY; CD8 ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; EPIRUBICIN; FLUOROURACIL; HIGH MOBILITY GROUP B1 PROTEIN; IDARUBICIN; METHOTREXATE; MITOXANTRONE; MORPHOLINYLDOXORUBICIN; NEMORUBICIN; PACLITAXEL; PLATINUM; PREDNISONE; SMALL INTERFERING RNA; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; ADVANCED CANCER; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL MEMBRANE; COLON CARCINOMA; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENDOMETRIUM CANCER; FOLLICULAR LYMPHOMA; GLIOBLASTOMA; HEAD AND NECK TUMOR; HODGKIN DISEASE; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; KAPOSI SARCOMA; KIDNEY CANCER; LEUKEMIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOKINE ACTIVATED KILLER CELL; MONOTHERAPY; MULTIPLE MYELOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SOFT TISSUE SARCOMA; STOMACH CARCINOMA; T CELL LYMPHOMA; THYMOMA; TRANSITIONAL CELL CARCINOMA; WHOLE BODY RADIATION;

ANTHRACYCLINES; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASMS;

EID: 41549145181     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2008.02.002     Document Type: Review

References (119)

1. Shapiro C.L., and Recht A. Side effects of adjuvant treatment of breast cancer. N. Engl. J. Med. 344 (2001) 1997-2008
2. Silvestrini R., and Gaetani M. Action of daunomycin on the nucleic metabolism of Ehrlich ascites tumor. Tumori 49 (1963) 389-397
3. Schwartz H.S., and Grindey G.B. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res. 33 (1973) 1837-1844
4. Ho R.L., et al. Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas. Oncol. Res. 5 (1993) 373-381
5. Ehrke M.J., et al. Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol. Immunother. 45 (1998) 287-298
6. Ehrke M.J., et al. Protective specific immunity induced by doxorubicin plus TNF-α combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Int. J. Cancer 87 (2000) 101-109
7. Lake R.A., and van der Most R.G. A better way for a cancer cell to die. N. Engl. J. Med. 354 (2006) 2503-2504
8. Casares N., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202 (2005) 1691-1701
9. Obeid M., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13 (2007) 54-61
10. Apetoh L., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13 (2007) 1050-1059
11. Albert M.L., et al. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
12. Albert M.L., et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4 (1998) 1321-1324
13. Shapiro D.M., et al. Quantitative biochemical differences between tumor and host as a basis for cancer chemotherapy. V. Niacin and 6-aminonicotinamide. Cancer Res. 17 (1957) 600-604
14. Orsini F., et al. Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res. 37 (1977) 1719-1726
15. Stoychkov J.N., et al. Effects of adriamycin and cyclophosphamide treatment on induction of macrophage cytotoxic function in mice. Cancer Res. 39 (1979) 3014-3017
16. Haskill J.S. Adriamycin-activated macrophages as tumor growth inhibitors. Cancer Res. 41 (1981) 3852-3856
17. Maccubbin D.L., et al. Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions. Cancer Immunol. Immunother. 31 (1990) 373-380
18. Maccubbin D.L., et al. Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res. 52 (1992) 3572-3576
19. Zaleskis G., et al. Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study. Oncol. Res. 6 (1994) 183-194
20. Fisk B., and Ioannides C.G. Increased sensitivity of adriamycin-selected tumor lines to CTL-mediated lysis results in enhanced drug sensitivity. Cancer Res. 58 (1998) 4790-4793
21. Ujhazy P., et al. Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunol. Immunother. 52 (2003) 463-472
22. Mace K., et al. Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin. Cancer Res. 48 (1988) 130-136
23. Salup R.R., et al. Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy. J. Immunol. 138 (1987) 641-647
24. Lumsden A.J., et al. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-γ. Anticancer Res. 16 (1996) 1145-1154
25. Lumsden A.J., et al. Improved efficacy of doxorubicin by simultaneous treatment with interferon-γ and interleukin-2. In Vivo 6 (1992) 553-558
26. Zagozdzon R., et al. Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int. J. Cancer 77 (1998) 720-727
27. Le Cesne A., et al. Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?. J. Immunother. 22 (1999) 268-277
28. Smalley R.V., et al. Interferon α combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N. Engl. J. Med. 327 (1992) 1336-1341
29. Solal-Celigny P., et al. Recombinant interferon α-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N. Engl. J. Med. 329 (1993) 1608-1614
30. Raitanen M.P., and Lukkarinen O. A controlled study of intravesical epirubicin with or without α 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group. Br. J. Urol. 76 (1995) 697-701
31. Ferrari P., et al. Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-α 2b versus interferon-α 2b with epirubicin. Anticancer Drugs 3 Suppl. 1 (1992) 25-27
32. Uekado Y., et al. The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guerin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report. Cancer Chemother. Pharmacol. 35 Suppl. (1994) S65-S68
33. Naglieri E., et al. Standard interleukin-2 (IL-2) and interferon-α immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma. Anticancer Res. 18 (1998) 2021-2026
34. Zitvogel L., et al. Immune response against dying tumor cells. Adv. Immunol. 84 (2004) 131-179
35. Zitvogel L., et al. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6 (2006) 715-727
36. Ullrich E., et al. Tumor stress, cell death and the ensuing immune response. Cell Death Differ. 15 (2008) 21-28
37. Tesniere A., et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15 (2008) 3-12
38. Scheffer S.R., et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int. J. Cancer 103 (2003) 205-211
39. Bartholomae W.C., et al. T cell immunity induced by live, necrotic, and apoptotic tumor cells. J. Immunol. 173 (2004) 1012-1022
40. Zitvogel L., et al. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8 (2008) 59-73
41. + T cells by exogenous cell-associated antigens. Immunity 17 (2002) 211-220
42. Williams D.B. Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum. J. Cell Sci. 119 (2006) 615-623
43. 2+-binding chaperone of the endoplasmic reticulum. Int. J. Biochem. Cell Biol. 37 (2005) 260-266
44. Gardai S.J., et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123 (2005) 321-334
45. Obeid M., et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol. Rev. 220 (2007) 22-34
46. Obeid M., et al. Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis. Cell Death Differ. 14 (2007) 1848-1850
47. Spisek R., et al. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 109 (2007) 4839-4845
48. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12 (1994) 991-1045
49. Janeway Jr. C.A. How the immune system works to protect the host from infection: a personal view. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 7461-7468
50. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1 (2001) 135-145
51. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6 (2006) 823-835
52. Apetoh L., et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 220 (2007) 47-59
53. Shiratsuchi A., et al. Inhibitory effect of Toll-like receptor 4 on fusion between phagosomes and endosomes/lysosomes in macrophages. J. Immunol. 172 (2004) 2039-2047
54. Tsan M.F., and Gao B. Endogenous ligands of Toll-like receptors. J. Leukoc. Biol. 76 (2004) 514-519
55. Marshak-Rothstein A., and Rifkin I.R. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu. Rev. Immunol. 25 (2007) 419-441
56. Erlandsson Harris H., and Andersson U. Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. Eur. J. Immunol. 34 (2004) 1503-1512
57. Dumitriu I.E., et al. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur. J. Immunol. 35 (2005) 2184-2190
58. Rovere-Querini P., et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5 (2004) 825-830
59. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56 (2007) 641-648
60. Nefedova Y., et al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 67 (2007) 11021-11028
61. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11 (2005) 6713-6721
62. Ramiro E., et al. Flavonoids from Theobroma cacao down-regulate inflammatory mediators. J. Agric. Food Chem. 53 (2005) 8506-8511
63. Aragon-Ching J.B., et al. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front. Biosci. 12 (2007) 4957-4971
64. Zusman I. Soluble tumor-associated antigens in cancer detection, prevention and therapy. Med. Sci. Monit. 10 (2004) RA317-RA324
65. Nakamura M., et al. Role of the Fas/FasL pathway in combination therapy with interferon-α and fluorouracil against hepatocellular carcinoma in vitro. J. Hepatol. 46 (2007) 77-88
66. Kim J.Y., et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp. Mol. Med. 38 (2006) 474-484
67. Dave S.S., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351 (2004) 2159-2169
68. + regulatory T cells. Clin. Cancer Res. (in press)
69. Frenzel H., et al. Toll-like receptor interference in myeloid dendritic cells through head and neck cancer. Anticancer Res. 26 (2006) 4409-4413
70. Arbour N.C., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25 (2000) 187-191
71. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6 (2006) 295-307
72. Terme, M. et al. NK cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. (in press)
73. Dimarco A., et al. Experimental studies of the antineoplastic activity of a new antibiotic, daunomycin. Tumori 49 (1963) 203-217
74. Massimo L., et al. Preliminary results of the therapeutic effectiveness in leukemia and malignant tumors in children of a new antineoplastic antibiotic: 'daunomycin'. Arch. Ital. Patol. Clin. Tumori 10 (1967) 3-19
75. Monfardini S., et al. Clinical trials with adriamycin in leukemia and solid tumors. Tumori 55 (1969) 197-216
76. Formelli F., et al. Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors. Cancer Chemother. Pharmacol. 3 (1979) 261-269
77. Bonfante V., et al. Preliminary clinical experience with 4-epidoxorubicin in advanced human neoplasia. Recent Results Cancer Res. 74 (1980) 192-199
78. Alberts D.S., et al. Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug. Cancer Chemother. Pharmacol. 5 (1980) 11-15
79. Rabbani A., et al. The anthracycline antibiotics: antitumor drugs that alter chromatin structure. Bioessays 27 (2005) 50-56
80. Batist G., et al. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin. Pharmacother. 3 (2002) 1739-1751
81. Gabizon A., et al. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42 (2003) 419-436
82. Glae G.R., et al. Combination chemotherapy of L1210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents. J. Natl. Cancer Inst. 57 (1976) 1363-1366
83. Rose P.G. Endometrial carcinoma. N. Engl. J. Med. 335 (1996) 640-649
84. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 351 (2004) 2519-2529
85. Hortobagyi G.N. Treatment of breast cancer. N. Engl. J. Med. 339 (1998) 974-984
86. Armitage J.O. Treatment of non-Hodgkin's lymphoma. N. Engl. J. Med. 328 (1993) 1023-1030
87. Cunningham D., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355 (2006) 11-20
88. Minotti G., et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 (2004) 185-229
89. Levine M.N., et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J. Clin. Oncol. 23 (2005) 5166-5170
90. Poole C.J., et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N. Engl. J. Med. 355 (2006) 1851-1862
91. Hayes D.F., et al. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 357 (2007) 1496-1506
92. Pritchard K.I., et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 354 (2006) 2103-2111
93. Tanner M., et al. Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J. Clin. Oncol. 24 (2006) 2428-2436
94. Rouzier R., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11 (2005) 5678-5685
95. Habeshaw T., et al. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. J. Clin. Oncol. 9 (1991) 295-304
96. Harris L., et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94 (2002) 25-36
97. Batist G., et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19 (2001) 1444-1454
98. Berman E., et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77 (1991) 1666-1674
99. Vogler W.R., et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J. Clin. Oncol. 10 (1992) 1103-1111
100. Arlin Z., et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 4 (1990) 177-183
101. Bassan R., et al. The use of anthracyclines in adult acute lymphoblastic leukemia. Haematologica 80 (1995) 280-291
102. Alexanian R., and Dimopoulos M. The treatment of multiple myeloma. N. Engl. J. Med. 330 (1994) 484-489
103. Rigacci L., et al. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk. Lymphoma 44 (2003) 1911-1917
104. Tsukasaki K., et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J. Clin. Oncol. 25 (2007) 5458-5464
105. Ferme C., et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N. Engl. J. Med. 357 (2007) 1916-1927
106. Northfelt D.W., et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol. 16 (1998) 2445-2451
107. Gill P.S., et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 14 (1996) 2353-2364
108. Valdivieso M., et al. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. J. Clin. Oncol. 2 (1984) 207-214
109. Onoda S., et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J. Clin. Oncol. 24 (2006) 5448-5453
110. Gordon A.N., et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19 (2001) 3312-3322
111. Santoro A., et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 13 (1995) 1537-1545
112. du Bois A., et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol. Oncol. 107 (2007) 518-525
113. Valteau-Couanet D., et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J. Clin. Oncol. 23 (2005) 532-540
114. Tannock I.F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351 (2004) 1502-1512
115. Sessa C., et al. Ongoing phase I and II studies of novel anthracyclines. Cardiovasc. Toxicol. 7 (2007) 75-79
116. Quintieri L., et al. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin. Cancer Res. 11 (2005) 1608-1617
117. Fabel K., et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92 (2001) 1936-1942
118. Harrington K.J., et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur. J. Cancer 37 (2001) 2015-2022
119. Leroux J.Y., et al. Enhancement of murine lymphoma cell lysability by CTL and by LAK cells, after treatments with mitomycin C and with adriamycin. Int. J. Immunopharmacol. 8 (1986) 369-375